Nitric oxide production stimulated by the basic fibroblast growth factor requires the synthesis of ceramide

Annals of the New York Academy of Sciences

Volumn 973, Issue , 2002, Pages 94-104

  Arena, Sara ^a,b   Pattarozzi, Alessandra ^a,b   Thellung, Stefano ^a,b   Villa, Valentina ^a,b   Corsaro, Alessandro ^a,b   Massa, Alessandro ^a,b   Diana, Fabrizio ^a,b   Spoto, Giuseppe ^c   Forcella, Sabrina ^c   Damonte, Gianluca ^b   Filocamo, Mirella ^d   Benatti, Umberto ^b   Schettini, Gennaro ^a,b   Florio, Tullio ^a,c  

^a CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d G GASLINI INSTITUTE   (Italy)

Author keywords

bFGF; Ceramide; Nitric oxide

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHELATING AGENT; CALCIUM ION; CALMODULIN; CAVEOLIN 1; CERAMIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; DESIPRAMINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE;

ANIMAL CELL; CELL MEMBRANE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; ENZYME ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPOGENESIS; MASS SPECTROMETRY; NIEMANN PICK DISEASE; NONHUMAN;

ANIMALIA;

EID: 0036961878     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04614.x     Document Type: Conference Paper

References (35)

1. MONCADA, S. & A. HIGGS. 1993. The L-arginine nitric oxide pathway. N. Engl. J. Med. 329: 2002-2012.
2. JAFFREY, S.R. & S.H. SNYDER. 1995. Nitric oxide: a neural messenger. Annu. Rev. Cell. Dev. Biol. 11: 417-440.
3. MARLETTA, M. 1994. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78: 927-930.
4. NATHAN, C. & Q. XIE. 1994. Nitric oxide synthases: roles, tolls and controls. Cell 78: 915-918.
5. MONCADA, S., R.M. PALMER & E.A. HIGGS. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43: 109-142.
6. FORSTERMANNN, U., J. BOISSEL & H. KLEINERT. 1998. Expressional control of the constitutive isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 12- 773-790.
7. GARCIA-CARDENA, G., R. FAN, D. STERN, et al. 1996. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin 1. J. Biol. Chem. 271: 27237-27240.
8. FLEMING, I. & R. BUSSE. 1999. Signal transduction of eNOS activation. Cardiovasc. Res. 43: 532-541.
9. FERON, O., H. BELHASSEN, L. KOBZIK, et al. 1996. Endothelial nitric oxide synthase targeting in caveolae: specific interaction with caveolin isoforms in cardiac monocytes and endothelial cells. J. Biol. Chem. 271: 22810-22814.
10. SHAUL, P.W., E.J. SMART, L.J. ROBINSON, et al. 1996. Acylation targets endothelial nitric oxide synthase to plasmalemma caveolae. J. Biol. Chem. 271: 6518-6522.
11. ANDERSON, R.G.W. 1998. The caveolae membrane system. Annu. Rev. Biochem. 67: 199-225.
12. HANNUN, Y.A. 1994. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269: 3125-3128.
13. KOLESNICK, R. & Z. FUKS. 1995. Ceramide: a signal for apoptosis or mitogenesis. J. Exp. Med. 181: 1949-1952.
14. ROTHBERG, K.G., J.E. HEUSER, W.C. DONZELL, et al. 1992. Caveolin a protein component of caveolae membrane coats. Cell 68: 673-682.
15. SCHERER, P.E., T. OKAMOTO, M. CHUN, et al. 1996. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc. Natl. Acad. Sci USA 93: 131-135.
16. TANG, Z., P. SHERER, T. OKAMOTO, et al. 1996. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J. Biol. Chem. 268: 9-12.
17. IGARASHI, J., H.S. THATTE, P. PRABHAKAR, et al. 1999. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc. Natl. Acad. Sci. USA 96: 12583-12588.
18. ZHANG, Y. & R. KOLESNICK. 1995. Signalling through the sphingomyelin pathway. Endocrinology 136: 4157-4160.
19. FLORIO, T., H. YAO, K.D. CAREY, et al. 1999. Somatostatin activation of MAP kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 13: 24-37.
20. LANDGREN, E., P. KLINT, K. YOKOTE, et al. 1998. Fibroblast growth factor receptor-1 mediates chemotaxis independently of direct SH2-domain protein binding. Oncogene 17: 283-291.
21. SCHMIDT, N.O., M. WESTPHAL, C. HAGEL, et al. 1999. Levels of vascular endothelial growth factor, hepathocyte growth factor/scatter factor, and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 84: 10-18.
22. BERSEN, H. & A.J. VAN DER KOGEL. 1999. Antiangiogenic therapy in brain tumor models. J. Neuro-oncol. 45: 247-255.
23. ZICHE, M., L. MORBIDELLI, R. CHOUNDOURI, et al. 1997. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced, but not basic fibroblast growth factor-induced, angiogenesis. J. Clin. Invest. 99: 2625-2634.
24. CORDELIER, P., J.-P. ESTEVE, N. RIVARD, et al. 1999. The activation of neuronal NO synthase is mediated by G-protein βγ subunit and the tyrosine phosphatase SHP-2. FASEB J. 13: 2037-2050.
25. 2 purinergic receptor subtypes. Life Sci. 64: 1661-1674.
26. SPOTO, G., S. BERARDI, G. AJERBA, et al. 1994. A reverse-phase HPLC method for cyclic nucleotide phosphodiesterases activity and classification. Adv. Exp. Med. Biol. 370: 815-820.
27. FOLCH, J., M. LESS & H.S. STANLEY. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226: 497-509.
28. KALHORN, T. & R.A. ZAGER. 1999. Renal cortical ceramide patterns during ischemic and toxic injury: assessments by HPLC-mass spectrometry. Am. J. Physiol. 277 (Renal Physiol. 46): F723-F733.
29. REES, D.D., R.M. PALMER, R. SCHULZ, et al. 1990. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro. Br. J. Pharmacol 101: 746-752.
30. BIELAWSKA, A., H.M. CRANE, D. LIOTTA, et al. 1993. Selectivity of ceramide-mediated biology. J. Biol. Chem. 268: 26226-26232.
31. WIEGMANN, K., S. SCHUTZE, T. MACHEIDT, et al. 1994. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor. Cell 78: 1005-1015.
32. WANG, E., W.P. NORRED, C.W. BACON, et al. 1991. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J. Biol. Chem. 266: 14486-14490.
33. ALBOUZ, S., M. VANIER, J. HAUW, et al. 1983. Effect of tricyclic antidepressant on sphingomyelinase and other sphingolipid hydrolases in C6 cultured glioma cells. Neurosci. Lett. 36: 311-315.
34. DENADAI, C., P. SESTILI, O. CANTONI, et al. 2000. Nitric oxide inhibits tumor necrosis factor-A-induced apoptosis by reducing the generation of ceramide. Proc. Natl. Acad. Sci. USA 97: 5840-5845.
35. OLIVERA, A., N.E. BUCKLEY & S. SPIEGEL. 1992. Sphingomyelinase and cell-permeable ceramide analogs stimulate cellular proliferation in quiescent Swiss 3T3 fibroblasts. J. Biol. Chem. 261: 26121-26127.